AstraZeneca plc (AZN) PT Set at GBX 4,000 by Goldman Sachs Group Inc.
AstraZeneca plc (LON:AZN) has been given a GBX 4,000 ($52.21) price target by investment analysts at Goldman Sachs Group Inc. in a note issued to investors on Tuesday. The brokerage presently has a a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price target points to a potential downside of 20.67% from the stock’s previous close.
A number of other analysts also recently commented on AZN. Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research report on Monday, June 6th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Monday, June 6th. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a research report on Tuesday, June 7th. JPMorgan Chase & Co. set a GBX 3,900 ($50.91) price objective on AstraZeneca plc and gave the company a “neutral” rating in a research report on Tuesday, June 7th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 4,950 ($64.61) price objective on shares of AstraZeneca plc in a research report on Thursday, June 9th. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5042.00 on Tuesday. The stock’s market capitalization is GBX 63.78 billion. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The company’s 50-day moving average price is GBX 5,006.61 and its 200-day moving average price is GBX 4,427.08.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.